Hormonal
Low circulating adiponectin levels are independently associated with the severity of liver histology (steatosis, necroinflammation, and fibrosis) in non-obese, non-diabetic patients with NASH, and this hypoadiponectinemia predicts impaired postprandial lipid metabolism.
For individuals with NASH, especially those who are not obese, maintaining higher levels of adiponectin is crucial for liver health. This can be supported by a diet higher in polyunsaturated fatty acids (PUFA) and lower in saturated fats, as PUFA intake was found to independently predict higher fasting adiponectin levels. Focus on dietary fat quality rather than just total fat or calories.
Circulating adiponectin was lower in NASH compared with controls... and on multiple regression analysis correlated negatively with liver steatosis, necroinflammation... and fibrosis... hypoadiponectinemia is present before overt diabetes and obesity appear and correlates with the severity of liver histology in NASH.
Why this rating
The study uses biopsy-proven NASH, rigorous statistical controls (multiple regression), and a specific physiological challenge (oral fat load), though it is cross-sectional.
Source
Adipokines in NASH: Postprandial Lipid Metabolism as a Link Between Adiponectin and Liver Disease *
Giovanni Musso et al. · Hepatology · 2005
DOI 10.1002/hep.20896
More from this paper
- Impaired postprandial lipid metabolism, characterized by higher triglyceride and free fatty acid responses to an oral fat load, is linked to hypoadiponectinemia and independently predicts the severity of hepatic steatosis in NASH patients.Good
- Dietary intake of polyunsaturated fatty acids (PUFA) is positively associated with fasting adiponectin levels, while saturated fatty acid (SFA) intake is negatively associated, suggesting that dietary fat quality modulates adiponectin secretion.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →